Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms: MY1B

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $129 | In Stock | In Stock | |
| 5 mg | $321 | In Stock | In Stock | |
| 10 mg | $511 | In Stock | In Stock | |
| 25 mg | $1,020 | In Stock | In Stock |
| Description | MY-1B is a covalent inhibitor and an inhibitor of RNA methyltransferase NSUN2 (IC50 = 1.3 μM), featuring stereoselectivity, covalent binding to C271 of NSUN2, and the ability to target PSME1, disrupt proteasome regulatory complexes, and downregulate presentation of specific MHC-I subtypes. |
| Targets & IC50 | NSUN2 methyltransferase:67 ± 15 M (Kinact/Ki), NSUN2:1.3 μM, NSUN2:2.4 µM (RNA methylation assays) |
| In vitro | Methods: The inhibitory effect of MY-1B (2.5–20 µM, 0–2000 seconds) on NSUN2 methyltransferase activity was determined by enzyme kinetic assays. Results: MY-1B inhibited NSUN2 activity with a Kinact/Ki value of 67 ± 15 M⁻¹.[1] Methods: In HEK293T cells, MY-1B (6.25–100 μM) was used to treat for 2 hours to assess binding to C1113 of DCAF1 protein. Results: MY-1B served as a stereo- and site-selective covalent ligand for C1113 of DCAF1.[2] Methods: In human prostate cancer cell lines, MY-1B (5 or 20 µM) was used to treat for 3 hours to assess binding to C271 of NSUN2 protein. Results: MY-1B bound to C271 of NSUN2 with stereoselectivity and site specificity.[3] |
| Synonyms | MY1B |
| Molecular Weight | 436.3 |
| Formula | C22H18BrN3O2 |
| Cas No. | 2929308-79-0 |
| Smiles | C(NC=1C2=C(C=CC1)C=CC=N2)(=O)[C@H]3[C@H](CN3C(C=C)=O)C4=CC=C(Br)C=C4 |
| Relative Density. | no data available |
| Storage | Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (183.36 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.56 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.